| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.063 | 0.2 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.056 | 0.2 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.2 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |